Copyright 2024
| PMID | Allele | Disease | Population | Drug Names | SNP | Class | Sentence |
|---|---|---|---|---|---|---|---|
| 3535929 | HLA (HLA) | transplantation | NA | NA | NA | unclassified | |
| histocompatible unrelated volunteer donors compared with hla nonidentical family donors in marrow transplantation for aplastic anemia and leukemia. | |||||||
| 3535929 | HLA (HLA) | leukemia | NA | NA | NA | unclassified | |
| histocompatible unrelated volunteer donors compared with hla nonidentical family donors in marrow transplantation for aplastic anemia and leukemia. | |||||||
| 3535929 | HLA (HLA) | aplastic anemia | NA | NA | NA | unclassified | |
| histocompatible unrelated volunteer donors compared with hla nonidentical family donors in marrow transplantation for aplastic anemia and leukemia. | |||||||
| 3535929 | HLA (HLA) | leukemia | NA | NA | NA | negation | |
| we conclude that unrelated donor bone marrow transplantation (bmt) should be considered in those cases of leukemia or bone marrow failure in which the chance of cure using conventional therapy is remote and a hla genotypically or phenotypically matched family donor is not available. | |||||||
| 3535929 | HLA (HLA) | bone marrow transplantation | NA | NA | NA | negation | |
| we conclude that unrelated donor bone marrow transplantation (bmt) should be considered in those cases of leukemia or bone marrow failure in which the chance of cure using conventional therapy is remote and a hla genotypically or phenotypically matched family donor is not available. | |||||||
| 3535929 | HLA (HLA) | bone marrow failure | NA | NA | NA | negation | |
| we conclude that unrelated donor bone marrow transplantation (bmt) should be considered in those cases of leukemia or bone marrow failure in which the chance of cure using conventional therapy is remote and a hla genotypically or phenotypically matched family donor is not available. | |||||||
| 3536547 | HLA MATCHED (HLA-MATCHED) | transplantation | NA | NA | NA | unclassified | |
| thirty patients who had major abo blood group incompatibility with their hla-matched donors underwent allogeneic marrow transplantation after removal of red blood cells (rbc) from donor marrow by ficoll-diatrazoate (f-d) separation using the ibm 2991 blood cell processor. | |||||||
| 3537654 | HLA-DR (HLA-DR) | transplantation | NA | NA | NA | unclassified | |
| residual leukemia was present in the bone marrow after two induction courses of high-dose ara-c. she received a bone marrow transplant from an hla- and dr-identical sister and remains in complete remission more than 2 years after transplantation. | |||||||
| 3537654 | HLA-DR (HLA-DR) | leukemia | NA | NA | NA | unclassified | |
| residual leukemia was present in the bone marrow after two induction courses of high-dose ara-c. she received a bone marrow transplant from an hla- and dr-identical sister and remains in complete remission more than 2 years after transplantation. | |||||||
| 3538548 | HLA (HLA) | transplantation | NA | NA | NA | unclassified | |
| transplantation in the presence of a peak positive t cell crossmatch due to an anti-hla antibody might only be successful if the antibody in the peak serum is of the igm class. | |||||||
Copyright 2024